Back to News
Market Impact: 0.25
Nasus Pharma Consensus Price Target Decreased by 25.42% to $14.96
Source: Nasdaq
Analyst InsightsAnalyst EstimatesHealthcare & Biotech
Fintel-compiled aggregate analyst price target for Nasus Pharma (NYSEAM:NSRX) was revised to $14.96 per share, down 25.42% from the prior $20.06 estimate dated October 20, 2026. The article provides no explanation for the revision or reported share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Apple reports after the bell. Options traders expect a big move
- Why is Apple stock falling afterhours today?
- Mizuho lowers Lumentum stock price target on Marvell acquisition